2012312
print

Drug Profile, Screen with Reflex to Quantitation

PAIN RFX U
Example Reports
Negative
Positive

Ordering Recommendation

Use for general testing in contexts of compliance and/or abuse, primarily in the pain management population. Alternative testing strategies include Drug Profile, Targeted by Tandem Mass Spectrometry and Enzyme Immunoassay, Urine (2007479) and Drug Profile, Targeted with Interpretation by Tandem Mass Spectrometry and Enzyme Immunoassay, Urine (2009288).

This test does not distinguish between the delta-8 and delta-9 forms of THC or their metabolites.

New York DOH Approval Status

This test is New York state approved.

Specimen Required

Patient Preparation
Collect

Random Urine.

Specimen Preparation

Transfer 4 mL each into two (2) ARUP Standard Transport Tubes urine with no additives or preservatives. (Min: 2 mL each)

Storage/Transport Temperature

Refrigerated.

Unacceptable Conditions

Specimens exposed to multiple freeze/thaw cycles, Pharmaceutical preparation.

Remarks
Stability

Ambient: 1 week; Refrigerated: 1 month; frozen: 1 month

Methodology

Qualitative Enzyme Multiplied Immunoassay Technique (EMIT)/Quantitative Gas Chromatography-Mass Spectrometry (GC-MS)/Quantitative Gas Chromatography-Mass Spectrometry (GC-MS)/Quantitative Liquid Chromatography-Tandem Mass Spectrometry

Performed

Sun-Sat

Reported

1-8 days

Reference Interval

Interpretive Data

Flagging indicates a positive result; not that the result is abnormal.

Presumptive negative results for drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. The concentration at which the screening test can detect a drug or metabolite varies within a drug class.

For medical purposes only; not valid for forensic use.


Drugs covered and range of cutoff concentrations Screen
Amphetamines Methodology:  Immunoassay
Positive Cutoff: 300 ng/mL
Barbiturates Methodology:  Immunoassay
Positive Cutoff: 200 ng/mL
Benzodiazepines Methodology:  Immunoassay
Positive Cutoff: 200 ng/mL
Buprenorphine Methodology:  Immunoassay
Positive Cutoff: 5 ng/mL
Carisoprodol Methodology:  Immunoassay
Positive Cutoff: 100 ng/mL
Cocaine Methodology:  Immunoassay
Positive Cutoff: 150 ng/mL
Ethyl Glucuronide Methodology:  Immunoassay
Positive Cutoff: 500 ng/mL
Fentanyl Methodology:  Immunoassay
Positive Cutoff: 1 ng/mL
MDMA (Ecstasy) Methodology:  Immunoassay
Positive Cutoff: 500 ng/mL
Meperidine Methodology:  Immunoassay
Positive Cutoff: 200 ng/mL
Methadone Methodology:  Immunoassay
Positive Cutoff: 150 ng/mL
Opiates Methodology:  Immunoassay
Positive Cutoff: 300 ng/mL
Oxycodone Methodology:  Immunoassay
Positive Cutoff: 100 ng/mL
Phencyclidine Methodology:  Immunoassay
Positive Cutoff: 25 ng/mL
Propoxyphene Methodology:  Immunoassay
Positive Cutoff: 300 ng/mL
Tapentadol Methodology:  Immunoassay
Positive Cutoff: 200 ng/mL
Tramadol Methodology:  Immunoassay
Positive Cutoff: 100 ng/mL
THC (Cannabinoids) Methodology:  Immunoassay
Positive Cutoff: 50 ng/mL
Zolpidem Methodology:  Immunoassay
Positive Cutoff: 20 ng/mL

Compliance Category

Laboratory Developed Test (LDT)

Note

If the specimen screens positive, then Confirmation/Quantitation by GC/MS and/or LC-MS/MS will be added to confirm result. Additional charges apply.

Hotline History

N/A

CPT Codes

80307; if reflexed, add 80321; 80325; 80345; 80346; 80348; 80349; 80353; 80354; 80358; 80359; 80361; 80362; 80365; 80367; 80368; 80369; 80372; 80373; 83992 (Reflexed Alt Code: G0480 )

Are you an ARUP Client? Click here for your pricing.

Components

Component Test Code* Component Chart Name LOINC
0090386 Creatinine, Urine 2161-8
0092191 Amphetamines Screen, Urine 19261-7
0092192 Cocaine Screen, Urine 19359-9
0092194 Phencyclidine Screen, Urine 19659-2
0092195 THC (Cannabinoids) Screen, Urine 19292-2
0092196 Barbiturates Screen, Urine 19270-8
0092197 Benzodiazepines Screen, Urine 14316-4
0092198 Propoxyphene Screen, Urine 19429-0
0092199 Methadone Screen, Urine 19550-3
2005094 Opiates Screen, Urine 19295-5
2005102 Oxycodone/Oxymorphone Screen, Urine 58430-0
2007913 Ethyl Glucuronide Screen, Urine 58375-7
2012212 Screen, Urine Interpretation 54247-2
2012274 Buprenorphine Screen, Urine 93494-3
2012279 Carisoprodol Screen, Urine 21142-5
2012285 Fentanyl Screen, Urine 11235-9
2012289 Meperidine Screen, Urine 3746-5
2012295 Tapentadol Screen, Urine 72485-6
2012298 Tramadol Screen, Urine 19710-3
2012301 Zolpidem Screen, Urine 94104-7
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.

Aliases

  • See individual components
Drug Profile, Screen with Reflex to Quantitation